The U.S. Food and Drug Administration has granted regulatory approval to Moderna’s mFLUSIVA, marking the nation’s first messenger RNA-based seasonal influenza vaccine. The historic decision authorizes full approval for adults aged 50 to 64 and grants accelerated approval for individuals aged 65 and older, contingent on post-marketing clinical studies.
The approval represents a major technological leap for public health defenses. Traditional flu shots rely on egg- or cell-based manufacturing processes that require six to eight months to update each year. By contrast, mRNA technology enables manufacturers to retool vaccines within weeks, allowing public health agencies to respond rapidly to emerging or mismatched seasonal flu strains. In Phase 3 clinical trials involving over 40,000 participants, mFLUSIVA demonstrated nearly 27 percent higher efficacy in preventing seasonal influenza compared to standard-dose flu shots.
The FDA’s endorsement comes despite fierce opposition and lingering skepticism from Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy, a long-time critic of mRNA technology, previously canceled $500 million in federal mRNA research contracts in favor of traditional vaccine platforms. The shot also overcame earlier administrative resistance within the FDA after the agency initially issued a refusal-to-file letter regarding trial designs. However, the agency’s independent Vaccines and Related Biological Products Advisory Committee ultimately voted unanimously in favor of the shot, citing strong antibody generation and robust T-cell immune responses.
Moderna expects mFLUSIVA to be available at select retail pharmacies ahead of the upcoming 2026–2027 respiratory virus season. Health officials emphasize that while mRNA shots carry slightly higher rates of temporary local side effects such as injection-site pain or fatigue, the dramatically expanded manufacturing speed and superior immune response offer vital new defenses for vulnerable older populations facing evolving annual influenza threats.
Sources Used
- The Washington Post: A new type of flu shot is coming after FDA approves mRNA-based vaccine
- Stock Titan: Moderna Gets FDA Approval for mFLUSIVA Flu Vaccine
- WHBL / Reuters: US FDA approves first mRNA flu shot from Moderna
- MedicalBrief: FDA panel okays mRNA flu jab shot down by Kennedy
- Genetic Literacy Project: Politicizing science: RFK, Jr.’s FDA rejects review of Moderna’s effective seasonal mRNA flu vaccine
Disclaimer
Artificial Intelligence Disclosure & Legal Disclaimer
AI Content Policy.
To provide our readers with timely and comprehensive coverage, South Florida Reporter uses artificial intelligence (AI) to assist in producing certain articles and visual content.
Articles: AI may be used to assist in research, structural drafting, or data analysis. All AI-assisted text is reviewed and edited by our team to ensure accuracy and adherence to our editorial standards.
Images: Any imagery generated or significantly altered by AI is clearly marked with a disclaimer or watermark to distinguish it from traditional photography or editorial illustrations.
General Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service. In no event shall South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service.
The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice. The Company does not warrant that the Service is free of viruses or other harmful components.
